Clinical Trial Update: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a conditioning regimen with Iodine-131 tositumomab plus etoposide and cyclophosphamide, followed by autologous stem cell trans…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Cutaneous B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Etoposide (Etoposide)
• Tositumomab (Bexxar) (tositumomab)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-27